• A second confirmed complete response has been recorded in the ACCENT trial
• In advanced pancreatic cancer, a complete response is extremely rare
• The ACCENT trial is evaluating the Company's best-in-class FAK inhibitor narmafotinib in combination with chemotherapy

Amplia Therapeutics Limited (ASX: ATX) has announced further data from the ongoing ACCENT trial investigating the Company's best-in-class FAK inhibitor narmafotinib in advanced pancreatic cancer. A second patient of the 55 patients enrolled in the trial has recorded a confirmed complete response (CR). This follows the announcement earlier this week of a separate patient who achieved a pathological CR in the trial. A confirmed complete response is a formal designation of response where there is a complete disappearance of all tumour lesions that is maintained for >2 months. This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body. For example, the seminal study demonstrating efficacy of the chemotherapies gemcitabine and Abraxane in advanced pancreatic cancer reported only one (1) CR out of 431 patients. Amplia CEO and MD Dr Chris Burns commented that to see a second complete response in the ACCENT trial is really wonderful news, particularly given how rare these are observed in advanced pancreatic cancer. Along with the pathological CR announced earlier in the week, this outcome further demonstrates the promising activity narmafotinib, on top of standard-of-care, is showing in pancreatic cancer.